Antibodies reduction

The following protocol is based on the methods recommended by Thermo Fisher for use of the cyanine dye DyLight 649. Antibody reduction is based on the methods of Sun et al. (2005), which results in partially reduced bispecific immunoglobulin containing available thiols in the hinge region for labeling. 

Antibody reduction usually is done in the presence of EDTA to prevent re-oxidation of the sulfhydryls by metal catalysis. In phosphate buffer at pH 6-7 and 4°C, one report stated that the number of available thiols decreased only by about 7 percent in the presence of EDTA over a 40-hour time span. In the absence of EDTA, this sulfhydryl loss increased to 63-90 percent... 

Tan P, Mitchell DA, Buss TN, Holmes MA, et al. 2002. Super humanized antibodies Reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences Application to an anti-CD28. J Immunol. 169 1119-1125. 

Another phase-3 placebo-controlled trial called PEARL (Program Enabling Antibody Reduction in Lupus) was conducted in the USA in 317 patients with lupus nephritis, who were treated with abetimus 100 mg/week. The trial was completed in December 2002 and preliminary results were reported in February 2003. However, in April 2003, La Jolla Pharmaceuticals ended the trial, in order to conserve resources for the continued development of the drug. 

The fact that ceU culture-derived products are often injected into humans as therapeutic agents makes it imperative that there be no component in the final product that can pose a potential health risk to the patient. Health risks can be introduced into a product from many sources including the ceUs themselves raw materials, such as semm, media components, etc materials used in purification, eg, antibodies and external contamination. Eor a therapeutic product such risk factors are identified at the outset and ways of reducing them to acceptable levels are designed into the process. Before a product is released by the EDA the manufacturer has to demonstrate this risk reduction by rigorous validation of the process. 

The current models for the mode of action of T-cell-specific monoclonal antibodies are based on the observation that the administration of CD3 antibodies leads to a significant reduction of the number of CD3-positive T cells. On the one hand, CD3+ T cells were... 

Chemical reduction of the antibody results iu the productiou of both light aud heavy chaius, with the heavy chaius showiug the differeut levels of glycosyla-tion that are of iuterest. The HPLC system used to separate the fight and heavy chains consisted of a Poros Rl/H 100 x 2.1 nun column maintained at 60°C. Gradient elution was used from 90% of a 2% acetic acid solution (solvent A) 10% acetonitrile/2-propanol (70 30 vol/vol) (solvent B) to 25% solvent A 75% solvent B over 30 min at a flow rate of 0.5 mimin. ... 

Miller Scott (1985) reported marked reduction in thymus weight in rats fed dioctyltin dichloride for 8 or 12 weeks at a level of 75 mg/kg diet. Numbers of lymphocytes together with T cell subpopulations were reduced in treated rats, but no difference was seen in antibody response to sheep red blood cells in vivo. No evidence was foimd of in vitro cytocidal effects of dioctyltin dichloride on blood lymphocytes. Evans et al. (1986) dosed pregnant and non-pregnant rats for 3 weeks at 75 mg/kg diet and reported severe thymic atrophy and extensive vacuolation of reticuloendothelial cells in pregnant animals only. 

Homogeneous immunoassays rely on a change in the intensity of the label signal that occurs when labeled antigen binds with antibody. When the label is an antibody, a reduction in the rate of enzyme catalysis forms the basis for the assay. This technique... 

Treatment for PTLD is still controversial however, the most common treatment options include reduction of immunosuppression, chemotherapy,11,82 and anti-B cell monoclonal antibodies.79... 

Clinical trials have indicated that omalizumab, a recombinant humanized monoclonal IgE antibody approved for use in moderate to severe persistent asthma in patients with reactivity to a perennial allergen, is effective in the treatment of SAR.25-27 Omalizumab inhibits the binding of IgE to mast cell and basophil receptors, resulting in a reduction of allergic mediator release.25 Additionally, serum free IgE levels are decreased.2 27 In SAR patients, omalizumab improves quality of life and nasal symptoms and reduces antihistamine needs. The most effective dose in SAR appears to be omalizumab 300 mg administered subcutaneously every 3 to 4 weeks depending on baseline IgE levels.26,27... 

Intramuscular/subcutaneous for reduction in enzyme antibody effects L-Asparaginase... 

Pretreatment with monoclonal anti-TNF antibodies prevents mortality (B23, M32) and organ damage (M16) in experimental sepsis. In clinical studies using anti-TNF antibodies, however, the overall benefit of this treatment showed encouraging but no evident results (L22). Recently, the INTERSEPT study suggests a possible role for anti-TNF antibody as an adjunctive therapy, but with no reduction of mortality (C21). There is no plain cause-effect relation between TNF re-... 

---